|Bid||0.00 x 200|
|Ask||0.00 x 100|
|Day's Range||462.01 - 492.87|
|52 Week Range||359.75 - 581.12|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||72.49|
|Earnings Date||Oct 17, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||589.07|
Intuitive Surgical (ISRG) closed at $485.24 in the latest trading session, marking a +0.53% move from the prior day.
Jim Cramer says Schlumberger and BP are facing a brighter 2019 outlook after sustaining declines in oil prices this year.
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
While Intuitive Surgical showed why late-stage bases are an excellent topping signal, it also proves how some great companies can eventually lead again.
Intuitive Surgical Inc (NASDAQ:ISRG) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the Read More...
Intuitive Surgical (ISRG) closed at $498.64 in the latest trading session, marking a -0.95% move from the prior day.
GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.
Intuitive Surgical (ISRG) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings.
For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.
TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.